特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书_老虎社区_美港股上老虎

特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书

机器人网09-29

9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。

IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

小谷AI洞察
·09-29
图是假的，订单是真
回复
1
举报
ZL_146195
·09-29
这都几个世纪前的假新闻了，还跟这推送呢？
回复
1
举报
挣钱啊
·09-29
已经辟谣了
回复
1
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2571876624?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-29 08:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2571876624","market":"us","top_or_hot":-1,"title":"特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书","media":"机器人网","content":"<html><body><article><p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形<strong>机器人</strong>。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250929084817582d1632zyi9h0k9td\"/><p>IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。</p></article></body></html>","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-29 08:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b><strong>机器人网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823411888.USD","symbol_name":"法巴消费创新基金 Cap","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b","article_id":"2571876624","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571876624","pubTimestamp":1759106897,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0823411888.USD":"法巴消费创新基金 Cap","BK4534":"瑞士信贷持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","TSLA":"特斯拉","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4592":"伊斯兰概念","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","BK4588":"碎股","BK4550":"红杉资本持仓","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4551":"寇图资本持仓","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","TSLL":"Direxion Daily TSLA Bull 2X Shares","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4581":"高盛持仓","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4527":"明星科技股","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"translate_title":"Tesla is expected to receive a large order for 10,000 Optimus 3 + humanoid robots and has signed a letter of intent with plant-based pharmaceutical company PharmAGRI","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLA":1.5,"TSLL":1.5,"TSYW.SI":0.6},"content_text":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":483821210083400,"gmtCreate":1759149379498,"gmtModify":1759149381722,"author":{"id":"4138621111675080","authorId":"4138621111675080","name":"小谷AI洞察","avatar":"https://static.tigerbbs.com/ed34002d87b2f93e10d511702e995ab8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4138621111675080","authorIdStr":"4138621111675080"},"htmlText":"图是假的，订单是真","listText":"图是假的，订单是真","text":"图是假的，订单是真","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/483821210083400","repostId":2571876624,"repostType":2,"repost":{"id":"2571876624","kind":"news","pubTimestamp":1759106897,"share":"https://www.laohu8.com/m/news/2571876624?lang=&edition=full","pubTime":"2025-09-29 08:48","market":"us","language":"zh","title":"特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571876624","media":"机器人网","summary":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","content":"<html><body><article><p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形<strong>机器人</strong>。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250929084817582d1632zyi9h0k9td\"/><p>IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-29 08:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b><strong>机器人网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0823411888.USD":"法巴消费创新基金 Cap","BK4534":"瑞士信贷持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","TSLA":"特斯拉","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4592":"伊斯兰概念","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","BK4588":"碎股","BK4550":"红杉资本持仓","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4551":"寇图资本持仓","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","TSLL":"Direxion Daily TSLA Bull 2X Shares","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4581":"高盛持仓","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4527":"明星科技股","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2571876624","content_text":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","news_type":1,"symbols_score_info":{"TSLA":1.5,"TSLL":1.5,"TSYW.SI":0.6}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":483814016233728,"gmtCreate":1759147431212,"gmtModify":1759147433578,"author":{"id":"3546246254166095","authorId":"3546246254166095","name":"ZL_146195","avatar":"https://static.tigerbbs.com/ff5a73ca69b8b0252ef37cb58e4d4944","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3546246254166095","authorIdStr":"3546246254166095"},"htmlText":"这都几个世纪前的假新闻了，还跟这推送呢？","listText":"这都几个世纪前的假新闻了，还跟这推送呢？","text":"这都几个世纪前的假新闻了，还跟这推送呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/483814016233728","repostId":2571876624,"repostType":2,"repost":{"id":"2571876624","kind":"news","pubTimestamp":1759106897,"share":"https://www.laohu8.com/m/news/2571876624?lang=&edition=full","pubTime":"2025-09-29 08:48","market":"us","language":"zh","title":"特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571876624","media":"机器人网","summary":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","content":"<html><body><article><p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形<strong>机器人</strong>。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250929084817582d1632zyi9h0k9td\"/><p>IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-29 08:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b><strong>机器人网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0823411888.USD":"法巴消费创新基金 Cap","BK4534":"瑞士信贷持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","TSLA":"特斯拉","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4592":"伊斯兰概念","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","BK4588":"碎股","BK4550":"红杉资本持仓","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4551":"寇图资本持仓","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","TSLL":"Direxion Daily TSLA Bull 2X Shares","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4581":"高盛持仓","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4527":"明星科技股","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2571876624","content_text":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","news_type":1,"symbols_score_info":{"TSLA":1.5,"TSLL":1.5,"TSYW.SI":0.6}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":483665332879456,"gmtCreate":1759110984836,"gmtModify":1759110986999,"author":{"id":"3458578034495035","authorId":"3458578034495035","name":"挣钱啊","avatar":"https://static.tigerbbs.com/e8605c10a75170657aa20530a2ec46c0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3458578034495035","authorIdStr":"3458578034495035"},"htmlText":"已经辟谣了","listText":"已经辟谣了","text":"已经辟谣了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/483665332879456","repostId":2571876624,"repostType":2,"repost":{"id":"2571876624","kind":"news","pubTimestamp":1759106897,"share":"https://www.laohu8.com/m/news/2571876624?lang=&edition=full","pubTime":"2025-09-29 08:48","market":"us","language":"zh","title":"特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571876624","media":"机器人网","summary":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","content":"<html><body><article><p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形<strong>机器人</strong>。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20250929084817582d1632zyi9h0k9td\"/><p>IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n特斯拉有望获万台 Optimus 3+ 人形机器人大单，已同植物基制药企业 PharmAGRI 签署意向书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-29 08:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b><strong>机器人网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0823411888.USD":"法巴消费创新基金 Cap","BK4534":"瑞士信贷持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","TSYW.SI":"TESLA 3xLongSG261006","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","TSLA":"特斯拉","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2326559502.SGD":"Natixis Loomis Sayles US Growth Equity P/A SGD-H","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4592":"伊斯兰概念","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","BK4588":"碎股","BK4550":"红杉资本持仓","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","BK4551":"寇图资本持仓","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","TSLL":"Direxion Daily TSLA Bull 2X Shares","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4581":"高盛持仓","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LU1861215975.USD":"贝莱德新一代科技基金 A2","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","BK4527":"明星科技股","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929084822954b1b57&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2571876624","content_text":"9 月 18 日消息，美国植物基制药企业 PharmAGRI 在一份当地时间本月 15 日的新闻稿中表示，其已于特斯拉签署了一份意向书，计划在农场运营、原料药合成、处方药生产环节部署多达 1 万台特斯拉的 Optimus 3+ 人形机器人。IT之家注意到，特斯拉目前仅对外展出了 Optimus 2.5，而 Optimus 3+ 至少还要经过两次迭代才能问世，因此当前离 PharmAGRI 订单的实际交付还有数年时间。","news_type":1,"symbols_score_info":{"TSLA":1.5,"TSLL":1.5,"TSYW.SI":0.6}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":3,"repostSize":4,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}